Dianthus Therapeutics, Inc. /DE/
DNTH evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for DNTH—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · DNTH
Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing antibody therapeutics for complement-mediated diseases, with its lead candidate claseprubart in Phase 3 trials for generalized myasthenia gravis.
Key risk: Clinical trial failure risk
BioSniper Score
Based on 6 of 6 signals
Market Cap
$5.79B
Cash Runway
52.1 moLead Asset
claseprubart (Phase 2)Next Catalyst
Phase3_Topline · Oct 31, 2026Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 6 clinical trials · 3 catalysts for Dianthus Therapeutics, Inc. /DE/.
Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing antibody therapeutics for complement-mediated diseases, with its lead candidate claseprubart in Phase 3 trials for generalized myasthenia gravis.
- Lead product candidate claseprubart is being evaluated in a Phase 3 trial for generalized myasthenia gravis, with topline data expected by October 31, 2026 [catalyst].
- Cash, cash equivalents and investments totaled $1.2 billion as of June 30, 2026, expected to fund operations into 2030 [sec_mda · as of 2026-08-04].
- Net loss for the six months ended June 30, 2026 was $50.2M, and accumulated deficit reached $427.8 million as of that date [sec_mda · as of 2026-08-04].
- The company also has early-stage pipeline candidates DNTH212 and DNTH312, with Phase 2 trials initiated in 2024 [catalyst].
What works
- Cash runway extends into 2030, providing a long operational horizon without near-term financing pressure [sec_mda · as of 2026-08-04].
- Lead candidate claseprubart is in Phase 3 with a defined topline catalyst in late 2026, representing a potential value inflection point [catalyst].
What to weigh
- The company has a history of significant operating losses and negative cash flows, with an accumulated deficit of $427.8 million as of June 30, 2026 [sec_mda · as of 2026-08-04].
- Expenses are expected to continue increasing as clinical trials and manufacturing scale up, requiring additional capital if cash runway shortens [sec_mda · as of 2026-08-04].
- All product candidates are still in clinical development with no approved products or commercial revenue, making the company entirely dependent on trial outcomes [sec_mda · as of 2026-08-04].
From the filings
Quoted directly from source documents.
Cash runway extends into 2030
“Based on our current operating plan, we believe that our existing cash, cash equivalents and investments as of June 30, 2026 should be sufficient to fund our operations into 2030.”
SEC MD&A · August 4, 2026
Accumulated deficit of $427.8 million
“we had an accumulated deficit of $427.8 million.”
SEC MD&A · August 4, 2026
Expectation of continued significant expenses and operating losses
“We expect to continue to incur significant expenses and operating losses for the foreseeable future as we advance the clinical development of our lead product candidate, claseprubart, DNTH212, DNTH312, or any other future product candidates.”
SEC MD&A · August 4, 2026
Catalyst timeline
- 2026-10-31 · Phase3_Topline — Topline data from the Phase 3 trial of claseprubart in generalized myasthenia gravis will be a key readout for the company's lead candidate.
- 2030-12-31 · Phase3_Topline — A separate Phase 3 trial topline readout is scheduled, though details on the specific indication are not provided in the catalyst block.
- 2031-09-01 · Phase3_Topline — Another Phase 3 topline readout is listed, representing a later-stage catalyst for a different study.
Risks & what to watch (3)›
Key risks
- Clinical trial failure risk — All product candidates are in development; failure of Phase 3 trial for claseprubart could materially impair the company's prospects [sec_mda · as of 2026-08-04].
- Need for additional capital — Ongoing losses and increasing R&D costs may require future financing, which may not be available on favorable terms [sec_mda · as of 2026-08-04].
- Regulatory and commercial uncertainty — No approved products or commercial revenue; reliance on regulatory approval and market acceptance for any future product [sec_mda · as of 2026-08-04].
What to watch
- Phase 3 topline data for claseprubart in generalized myasthenia gravis expected by October 31, 2026 [catalyst].
- Progress of Phase 2 trials for DNTH212 and DNTH312, initiated in 2024 [catalyst].
- Any changes in cash position or financing activities as the company continues to incur operating losses [sec_mda · as of 2026-08-04].
Sources: Catalysts · SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run Dianthus Therapeutics, Inc. /DE/ through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Dianthus Therapeutics, Inc. /DE/ facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
52.1 months
D/E 0.04 · 0% dilution
Lead: Phase 3
2 candidates
3 upcoming, next in ~62d
0 buys · 53 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
240
Total value held
$4.91B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 7,767,686 | $651.9M |
| avidity partners management lp | 4,208,368 | $361.3M |
| vanguard capital management llc | 4,062,498 | $340.9M |
| blackrock, inc. | 3,175,703 | $266.5M |
| ra capital management, l.p. | 2,611,733 | $219.2M |
| wellington management group llp | 2,595,783 | $217.8M |
| citadel advisors llc | 1,648,983 | $138.4M |
| state street corp | 1,398,913 | $117.4M |
| venrock adviser, llc | 1,180,000 | $99.0M |
| fred alger management, llc | 1,161,923 | $97.5M |
Showing top 10 of 240 institutional holders of Dianthus Therapeutics, Inc. /DE/. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 13.9%
- Days to cover
- 6.3
- Shares short
- 6,564,599
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
DNTH short interestGovernance
Frequently asked questions
What is the AI investment thesis for Dianthus Therapeutics, Inc. /DE/?
Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing antibody therapeutics for complement-mediated diseases, with its lead candidate claseprubart in Phase 3 trials for generalized myasthenia gravis.
What is Dianthus Therapeutics, Inc. /DE/'s lead drug candidate?
Dianthus Therapeutics, Inc. /DE/'s most advanced tracked candidate is claseprubart (Phase 2) for Chronic Inflammatory Demyelinating Polyneuropathy; Multifocal Motor Neuropathy; Myasthenia Gravis, Generalized.
What is Dianthus Therapeutics, Inc. /DE/'s next catalyst?
Dianthus Therapeutics, Inc. /DE/'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to evaLua" — expected October 31, 2026.
Who is the CEO of Dianthus Therapeutics, Inc. /DE/?
Mr. Marino Garcia M.B.A. is the chief executive officer of Dianthus Therapeutics, Inc. /DE/ (DNTH).
Where is Dianthus Therapeutics, Inc. /DE/ headquartered?
Dianthus Therapeutics, Inc. /DE/ (DNTH) is headquartered in New York, NY, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.